Locally Advanced or Metastatic Renal Cell Carcinoma

Oncology
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
2 programs
1
CabozantinibPhase 2Small Molecule1 trial
Cabozantinib monotherapyN/A1 trial
Active Trials
NCT04353765Completed247Est. Jun 2020
NCT03945773Completed127Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenCabozantinib
IpsenCabozantinib monotherapy

Clinical Trials (2)

Total enrollment: 374 patients across 2 trials

NCT03945773IpsenCabozantinib

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Start: Jan 2020Est. completion: Feb 2026127 patients
Phase 2Completed
NCT04353765IpsenCabozantinib monotherapy

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Start: Jan 2020Est. completion: Jun 2020247 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space